AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38012450
Drug: Device-encapsulated pancreatic
RxNorm normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Device-encapsulated pancreatic precursor cells derived from human embryonic stem cells, 2-3-fold higher cell doses, optimized membrane perforation pattern.
Trial: 38012450
Drug: Continuous glucose
RxNorm normalized name: sub-q infusion pump w/continuous glucose monitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous glucose monitoring (CGM) and insulin dosing.
Trial: 38012534
Drug: Sotatercept (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotatercept (starting dose 0.3 mg/kg; target dose 0.7 mg/kg)
Trial: 38012682
Drug: Decitabine and
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine and ATRA (all-trans retinoic acid) combination therapy administered over 52 cycles
Trial: 38012795
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of amisulpride (100 mg)
Trial: 38012835
Drug: Pegfilgrastim 7.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegfilgrastim 7.2 mg
Trial: 38013135
Drug: Completely oral
RxNorm normalized name: Canker Complete Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Completely oral anticoagulation
Trial: 38013135
Drug: Sequential anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential anticoagulation with DOACs
Trial: 38013135
Drug: Sequential anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential anticoagulation with VKAs
Trial: 38013135
Drug: Completely parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Completely parenteral anticoagulation
Trial: 38013594
Drug: 4CMenB and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4CMenB and MenACWY vaccines (two doses, given 1 month apart)
Trial: 38014462
Drug: Brief Observable
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Observable Anxiety Sensitivity Treatment (BOAST) - a single clinician-led intervention session followed by a two-week ecological momentary intervention (EMI) via mobile app.
Trial: 38014691
Drug: High autoantibody
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High autoantibody concentrations targeting complement factor C3a receptor
Trial: 38014691
Drug: High autoantibody
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High autoantibody concentrations targeting vascular endothelial growth factor receptor-2
Trial: 38015220
Drug: Toripalimab (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab (240 mg) plus gemcitabine-cisplatin
Trial: 38015366
Drug: Elosan Cabin
RxNorm normalized name: Pogostemon cablin top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elosan Cabin C1 treatment (8 sessions over 9 weeks)
Trial: 38015467
Drug: Lenalidomide 15
RxNorm normalized name: lenalidomide 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 15 mg
Trial: 38015598
Drug: Smartwatch-smartphone dyad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartwatch-smartphone dyad for AF detection (Pulsewatch system) plus an electrocardiogram patch
Trial: 38015598
Drug: Electrocardiogram patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrocardiogram patch alone
Trial: 38015877
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment (control)
Trial: 38016021
Drug: BNT162b2-Omi.BA.4/BA.5 (30-µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2-Omi.BA.4/BA.5 (30-µg second booster)
Trial: 38016160
Drug: TB-ART treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TB-ART treatment
Trial: 38016322
Drug: Adjuvanted protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted protein vaccine (5, 15 or 45 μg)
Trial: 38016322
Drug: mRNA vaccine
RxNorm normalized name: RSV mRNA vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA vaccine (10, 20, or 50 μg)
Trial: 38016482
Drug: Pucotenlimab at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pucotenlimab at 200 mg every 3 weeks
Trial: 38016718
Drug: Intravenous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous trastuzumab (arm A)
Trial: 38016718
Drug: Subcutaneous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous trastuzumab (arm B)
Trial: 38016950
Drug: Nicotinamide riboside
RxNorm normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide riboside (NR) 1500 mg twice daily
Trial: 38017325
Drug: EMI-137 (0.09
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMI-137 (0.09 mg/kg, 0.13 mg/kg, 0.18 mg/kg)
Trial: 38017432
Drug: High levels
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High levels of IL-6 (≥9.5 pg/mL)
Trial: 38017500
Drug: Hydrolyzed collagen
RxNorm normalized name: Preprotein Hydrolyzed Collagen Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrolyzed collagen (10 g) and vitamin C (40 mg) supplementation for 24 weeks combined with progressive tendon loading exercises (PTLE)
Trial: 38017500
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 g maltodextrin) combined with progressive tendon loading exercises (PTLE)
Trial: 38017574
Drug: ReSeT intervention
RxNorm normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ReSeT intervention (online psychoeducational program and video therapy sessions)
Trial: 38017663
Drug: Perampanel as
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perampanel as add-on therapy
Trial: 38017663
Drug: Perampanel as
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perampanel as substitution therapy
Trial: 38018158
Drug: Daily egg
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily egg consumption for six months
Trial: 38018460
Drug: Tislelizumab (anti-PD-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab (anti-PD-1 antibody) added to radiation therapy
Trial: 38018840
Drug: IVUS-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVUS-guided treatment decision
Trial: 38018840
Drug: FFR-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FFR-guided treatment decision
Trial: 38019116
Drug: Giredestrant 30
RxNorm normalized name: Giredestrant
DrugBank: Giredestrant (DB19125)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Giredestrant 30 mg once daily
Trial: 38019116
Drug: Giredestrant 90
RxNorm normalized name: Giredestrant
DrugBank: Giredestrant (DB19125)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Giredestrant 90 mg once daily
Trial: 38019116
Drug: Giredestrant 100
RxNorm normalized name: Giredestrant
DrugBank: Giredestrant (DB19125)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Giredestrant 100 mg combined with palbociclib 125 mg
Trial: 38019116
Drug: Giredestrant 10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Giredestrant 10, 30, 90, or 250 mg once daily (dose-escalation stage)
Trial: 38019116
Drug: Giredestrant 30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Giredestrant 30, 100, and 250 mg once daily (dose-expansion stage)
Trial: 38019356
Drug: BI 1358894
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1358894 100 mg
Trial: 38019444
Drug: Metronomic oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic oral cyclophosphamide and methotrexate (CM) combined with bevacizumab (Arm A)
Trial: 38019444
Drug: Metronomic oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic oral cyclophosphamide and methotrexate (CM) alone (Arm B)
Trial: 38019467
Drug: Parent-led, telehealth-delivered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-led, telehealth-delivered cognitive behavioral therapy (CBT) program
Trial: 38019571
Drug: Sleep Treatment
RxNorm normalized name: Sleep
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sleep Treatment Education Program for Young Adult Cancer Survivors (STEP-YA)
Trial: 38019593
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Mindfulness-Based Exposure Therapy
Trial: 38019656
Drug: SARS-CoV-2 vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 vaccines (third doses)
Trial: 38019657
Drug: Tenofovir rectal
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tenofovir rectal douche 220 mg iso-osmolar product A
Trial: 38019657
Drug: Tenofovir rectal
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tenofovir rectal douche 660 mg iso-osmolar product B
Trial: 38019657
Drug: Tenofovir rectal
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tenofovir rectal douche 660 mg hypo-osmolar product C
Trial: 38019901
Drug: Filgotinib 200
RxNorm normalized name: nilotinib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgotinib 200 mg with concomitant immunomodulator (IM)
Trial: 38019956
Drug: Bacillus Calmette-Guérin
RxNorm normalized name: Bacillus Calmette-Guérin (BCG) vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus Calmette-Guérin (BCG) injection of 2 × 106 to 16 × 106 colony-forming units
Trial: 38019956
Drug: Bacillus Calmette-Guérin
RxNorm normalized name: Bacillus Calmette-Guérin (BCG) vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus Calmette-Guérin (BCG) injection
Trial: 38020288
Drug: Berotralstat (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berotralstat (150 mg daily)
Trial: 38021251
Drug: Rumination-focused cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rumination-focused cognitive behavioral therapy (RF-CBT)
Trial: 38021297
Drug: Amnion collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amnion collagen matrix wrap and bone marrow aspirate concentrate (BMAC) injection during graft preparation.
Trial: 38021373
Drug: Consecutive-day group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consecutive-day group (daily 100 mg iron for 90 d, followed by daily placebo for another 90 d)
Trial: 38021373
Drug: Alternate-day group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate-day group (same daily dose of iron and placebo on alternate days for 180 d)
Trial: 38023544
Drug: mRNA-1273 vaccine
RxNorm normalized name: SARS-CoV-2 mRNA-1273 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 vaccine (2 doses at months 0 and 1)
Trial: 38023544
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (receipt of COVID-19 vaccine)
Trial: 38023545
Drug: Better WASH
RxNorm normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Better WASH households (defined by safe source of water for daily use, safe source of drinking water, private/shared flush toilet use, and always handwashing with soap after defecation)
Trial: 38023553
Drug: Dolutegravir (DTG;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir (DTG; 50 mg once per day) plus Darunavir boosted with cobicistat (DRV/c; 800/150 mg once per day)
Trial: 38023556
Drug: Direct-acting antiviral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-acting antiviral treatments for HCV
Trial: 38023564
Drug: Third SARS-CoV-2
RxNorm normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third SARS-CoV-2 vaccine (mRNA-1273 or BNT162b2)
Trial: 38023564
Drug: Basic immunization
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic immunization (first and second vaccines)
Trial: 38024244
Drug: Cediranib (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib (20 mg) in combination with radiation and temozolomide
Trial: 38024244
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with radiation and temozolomide
Trial: 38025217
Drug: Drug-induced acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-induced acute kidney injury (DI-AKI) cases
Trial: 38025217
Drug: Nephrotoxic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nephrotoxic drugs (e.g., vancomycin, NSAIDs, piperacillin/tazobactam)
Trial: 38025806
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy for stage IIIA (30.2%) and stage IIIB (37.0%) patients
Trial: 38027106
Drug: Exenatide 2
RxNorm normalized name: exenatide 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide 2 mg weekly injections
Trial: 38027419
Drug: 0.2-μg/day fluocinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2-μg/day fluocinolone acetonide implant (FAi)
Trial: 38027469
Drug: Oral Ambroxol
RxNorm normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Ambroxol (ABX) 1.2 g/day
Trial: 38028146
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (40.4%)
Trial: 38028146
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus surgery (33.8%)
Trial: 38028146
Drug: Sequential chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemoradiotherapy (CRT) (17.6%)
Trial: 38028146
Drug: Concurrent CRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent CRT (9.3%)
Trial: 38028272
Drug: transcutaneous spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transcutaneous spinal stimulation-enhanced walking therapy (WALK)
Trial: 38028429
Drug: Remote electrical
RxNorm normalized name: remote electrical neuromodulation (REN) device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote electrical neuromodulation (REN) device used for acute treatment of migraine, applied for 45 minutes, used on at least 10 days every 28-day month
Trial: 38028977
Drug: Internet-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive-behavioral therapy (9 sessions)
Trial: 38028985
Drug: EBV-positive diffuse
RxNorm normalized name: Oldenlandia diffusa extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBV-positive diffuse large B-cell lymphoma treatment
Trial: 38028985
Drug: EBV-positive classic
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EBV-positive classic Hodgkin lymphoma treatment
Trial: 38029356
Drug: Recombinant erythropoietin
RxNorm normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant erythropoietin (rEPO) - Epoetin alpha 40,000 international units per week administered subcutaneously until hemoglobin (Hb) >11 g/dL and then tapered off.
Trial: 38029357
Drug: Fol-CHOP (pralatrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fol-CHOP (pralatrexate 30 mg/m2 combined with CHOP)
Trial: 38029807
Drug: p75NTR inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: p75NTR inhibitor LM11A-31
Trial: 38029831
Drug: Previous immune
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous immune checkpoint inhibitor therapy (ICI)
Trial: 38030258
Drug: 4 g EPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g EPA ethyl ester (icosapent ethyl (IPE; Vascepa)) daily
Trial: 38030303
Drug: NIS793 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIS793 plus spartalizumab (NIS793 0.3-30 mg/kg Q3W and spartalizumab 300 mg Q3W or NIS793 20-30 mg/kg Q2W and spartalizumab 400 mg Q4W)
Trial: 38030303
Drug: NIS793 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIS793 monotherapy (0.3-1 mg/kg every 3 weeks)
Trial: 38030303
Drug: NIS793 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIS793 plus spartalizumab (at recommended dose for expansion)
Trial: 38030319
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (10 μg/kg subcutaneously once a week for 8 weeks)
Trial: 38030962
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment (76.2% of participants)
Trial: 38031088
Drug: Schedule-I group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule-I group (3 DC injections with 28-day interval)
Trial: 38031088
Drug: Schedule-II group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule-II group (3 DC injections with 7-day interval for first course, then 28-day interval)
Trial: 38031584
Drug: 12 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 weeks of cognitive-behavioral therapy (CBT)
Trial: 38031584
Drug: 24 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 weeks of cognitive-behavioral therapy (CBT)
Trial: 38032573
Drug: Aficamten in
RxNorm normalized name: Aficamten
DrugBank: Aficamten (DB18490)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aficamten in addition to standard-of-care medications
Trial: 38032573
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in addition to standard-of-care medications
Trial: 38032624
Drug: Active hypoglossal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active hypoglossal nerve stimulation (HGNS) therapy
Trial: 38032624
Drug: Sham hypoglossal
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham hypoglossal nerve stimulation (HGNS) therapy
Trial: 38033143
Drug: Treatment goals
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment goals
Trial: 38033284
Drug: Bosutinib 400
RxNorm normalized name: bosutinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosutinib 400 mg/m
Trial: 38033284
Drug: Bosutinib 300
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib 300 mg/m
Trial: 38033284
Drug: Bosutinib 350
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib 350 mg/m
Trial: 38033375
Drug: tablet-based serious
RxNorm normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet-based serious game therapy (SGT), 4 months, four 20-min sessions/week
Trial: 38033459
Drug: Oral cannabidiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cannabidiol 600 mg/d
Trial: 38034010
Drug: Mediterranean (MED)
RxNorm normalized name: Thynnus mediterraneus flesh
DrugBank: Northern bluefin tuna (DB14162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean (MED) diet (hypocaloric, lower in carbohydrates, includes walnuts 28 g/day)
Trial: 38035363
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g specific collagen peptides (SCP)
Trial: 38035747
Drug: Icatibant (bradykinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icatibant (bradykinin inhibitor)
Trial: 38036487
Drug: Valganciclovir (dose-adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valganciclovir (dose-adjusted for renal clearance)
Trial: 38036712
Drug: Entinostat 8
RxNorm normalized name: entinostat
DrugBank: Entinostat (DB11841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entinostat 8 mg PO days 1 and 15 + Pembrolizumab 200 mg IV day 1 every 21 days
Trial: 38036720
Drug: Eftozanermin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eftozanermin alfa monotherapy 2.5-15 mg/kg on Day 1 or Days 1/8 of a 21-day cycle
Trial: 38036720
Drug: Eftozanermin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eftozanermin alfa monotherapy or combination therapy with oral venetoclax 400-800 mg daily (1.25-7.5 mg/kg Days 1/8/15 of a 21-day cycle)
Trial: 38036720
Drug: Eftozanermin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eftozanermin alfa (3.75 or 7.5 mg/kg Days 1/8/15/22 of a 28-day cycle) and FOLFIRI regimen with/without bevacizumab
Trial: 38036761
Drug: Bifidobacterium breve
RxNorm normalized name: Bifidobacterium Breve
DrugBank: Bifidobacterium breve (DB16549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium breve Bif195 (≥10 billion CFU) co-administered with aspirin 300 mg daily for 4 weeks